Aging, telomeres and heart failure by Wong, Liza S. M. et al.
Aging, telomeres and heart failure
Liza S. M. Wong • Pim van der Harst •
Rudolf A. de Boer • Jardi Huzen • Wiek H. van Gilst •
Dirk J. van Veldhuisen
Published online: 9 June 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract During normal aging, the heart undergoes
functional, morphological and cellular changes. Although
aging per se does not lead to the expression of heart failure,
it is likely that age-associated changes lower the threshold
for the manifestation of signs and symptoms of heart fail-
ure. In patients, the susceptibility, age of onset and pace of
progression of heart failure are highly variable. The pres-
ence of conventional risk factors cannot completely explain
this variability. Accumulation of DNA damage and telo-
mere attrition results in an increase in cellular senescence
and apoptosis, resulting in a decrease in the number and
function of cells, contributing to the overall tissue and
organ dysfunction. Biological aging, characterized by
reduced telomere length, provides an explanation for the
highly interindividual variable threshold to express the
clinical syndrome of heart failure at some stage during life.
In this review, we will elaborate on the current knowledge
of aging of the heart, telomere biology and its potential role
in the development of heart failure.
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Introduction
Congestive heart failure (CHF) is a highly prevalent con-
dition affecting more than 15 million patients in Europe
alone [1]. The incidence and prevalence of CHF increases
steeply with age and is likely to rise in the next decade due
to the increasing average age of the population [2]. The
prognosis of CHF is poor with a 4-year survival of only
*50% [1]. Advanced age is one of the major risk factors
for the development of CHF. Nevertheless, the suscepti-
bility, age of onset and pace of progression are highly
variable. The presence of conventional risk factors cannot
completely explain this variability. The process of bio-
logical aging affects most cells, organisms and species.
Although aging itself does not need to lead to CHF, it is
likely that age-associated changes lower the threshold for
the expression of this syndrome. Signiﬁcant changes in
diastolic function, hypertension, atherosclerosis, valve
calciﬁcations, senile cardiac amyloid depositions all are
associated with aging and an increased risk of the clinical
signs and symptoms of CHF [3]. The molecular mecha-
nisms involved allow time for accumulated damage to
occur and include free radicals, advance glycation end-
products, apoptosis and senescence. Accumulation of DNA
damage and telomere attrition can result in an increase in
senescent cells in tissue and organs and can subsequently
result in decreased function, providing an explanation for
the lower threshold to express the clinical manifestation of
heart failure. Here, we will brieﬂy overview the current
knowledge of the cardiac changes associated with aging.
One aspect of aging in relation to CHF is of particular
interest to us, telomere biology. Telomeres consist of an
evolutionary conserved repetitive nucleotide sequence and
are located at the terminal ends of the chromosomes [4, 5].
The process of telomere erosion has been put forward as an
L. S. M. Wong  P. van der Harst (&)  R. A. de Boer 
J. Huzen  W. H. van Gilst  D. J. van Veldhuisen
Division of Experimental Cardiology, Department of
Cardiology, University Medical Center Groningen, University of
Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
e-mail: p.van.der.harst@thorax.umcg.nl
123
Heart Fail Rev (2010) 15:479–486
DOI 10.1007/s10741-010-9173-7intracellular counting mechanism that runs parallel with the
aging process and the susceptibility to develop CHF.
Functional changes of the aging heart
At the functional level, there are no age-related changes in
cardiac output, end-diastolic or end-systolic volumes or
ejection fraction at rest in healthy subjects [6]. However,
the myocardial stiffness increases with advancing age,
resulting in an elevated left ventricular end-diastolic pres-
sure at rest and with exertion [7]. Early diastolic ﬁlling is
decreased in elderly, a phenomenon seen on echocardio-
graphy as a change of the early to late ﬁlling velocity (E/A
ratio) [8]. Important age-associated changes are particu-
larly noticeable during exercise. Although the stroke-vol-
ume increase during exercise of the young and old is
comparable, the old tend to augment stroke volume during
exercise more through cardiac dilatation with an increase in
end-diastolic volume, whereas the young rely more on
increase in the ejection fraction with no cardiac dilatation
[9]. During exercise, the older heart rate has a lesser
increase in frequency and blood pressure has a greater
increase [9]. The difference in heart rate response is
associated with a decrease in response to catecholamines
and axonal degeneration of sympathetic neurons innervat-
ing the atria [10, 11]. In addition, the number of pacemaker
cells in the sinoatrial node diminishes signiﬁcantly, from
around 50% in youth to less than 30% in elderly [12]. One
of the major vascular changes during aging is the decrease
in aortic distensibility and decrease in the ‘Windkessel
function’ explaining the frequently observed isolated sys-
tolic hypertension in elderly [7].
Morphological and cellular changes of the heart
The mature myocardium constitutes of cardiomyocytes and
supporting connective tissue [13]. Healthy cardiac tissue is
roughly composed of 20–25% cardiomyocytes, although
this number varies among different species [13]. During
aging, most components of the myocardium undergo
structural changes. The change in morphology is charac-
terized by a loss of myocytes number, with a subsequent
hypertrophy of remaining viable myocytes [14]. The
remaining myocytes frequently contain multiple nuclei
(polyploidy). The mechanism responsible for loss of
myocytes is likely to be apoptosis, or programmed cell
death. In parallel, there is an increase in collagen content,
ﬁbrosis and depositions of ‘senile’ cardiac amyloid and
lipofuscin [15–17]. Aging cardiomyocytes display pro-
longed contraction and relaxation caused by changes in
calcium homeostasis [18]. Prolonged contraction with
decreased force of the myoﬁlaments is associated with
down-regulation of genes that encode proteins that are
involved in contractile activity, such as troponin and
myosin forms in the aged heart [19, 20]. Age-related
changes of the mitochondria include a tendency to become
larger but less efﬁcient, with a decreased ATP production
per cell [21].
Cardiomyocyte turnover during aging
The paradigm that all cardiomyocytes are terminally dif-
ferentiated has been challenged. Recent experiments using
human left ventricular myocardial cells and carbon-dating
techniques have established that DNA of cardiomyocytes
continues to be synthesized many years after birth, indi-
cating that cells in the human heart do renew well into
adulthood [22]. Nevertheless, cardiomyocyte DNA syn-
thesis decreases with age. Mathematical modeling predicts
a *1% cardiomyocyte renewal rate at the age of 25 and
0.45% at the age of 75. Considering this turnover rate, at
the age of 50 years, 55% of the cardiomyocytes remain
from the time around birth. There was no signiﬁcant dif-
ference observed in
14C integration of DNA synthesis in
cardiomyocytes from subjects with cardiac pathology.
Interestingly, the
14C data also indicated a substantially
higher renewal rate for non-cardiomyocytes, with a median
annual turnover of 18%. Unfortunately, data derived from
14C integration do not allow the identiﬁcation of the source
of new cardiomyocytes. These could be derived either from
cardiomyocyte duplication or from some sort of progenitor
pool [22].
Advances in mouse genetic engineering allow cell
tracking using ‘fate-mapping’ approach. Cells expressing
the cardiomyocyte-speciﬁc alpha-myosin can be geneti-
cally labeled by an inducible recombination technique
leading to permanent GFP expression of only cells that
expressed alpha-myosin at time of induction [23]. If at a
later stage, stem cells (which initially do not express alpha-
myosin) contribute to cardiomyocyte renewal or regener-
ation, the percentage of GFP-positive myocytes will
decrease. These experiments indicated that stem cells do
not replace adult mouse cardiomyocytes during at least
1 year of aging. However, in the setting of myocardial
infarction or pressure-overloaded hearts, a signiﬁcant
decrease in percentage of GFP-positive myocytes was
observed, suggesting that precursor cells participate in the
formation of new cardiomyocytes after injury [23]. The
bone marrow is a pool for multiple types of progenitor
cells, which are believed to contribute to cardiovascular
repair [24]. Other possible sources of stem cells that can be
stimulated to cardiogenic differentiation are located in
adipose tissue or in the bone marrow [24].
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marrow progenitor cells is age. A study in young and old
bone marrow–derived endothelial progenitor cells (EPCs)
showed that endothelial progenitor cells from 3-month-old
donor mice augmented angiogenic capacity in the recipient
18-month-old mice, whereas EPCs from 18-month-old
donor mice showed no effect [25]. Furthermore, young
mesenchymal stem cells (MSCs) showed higher angiogenic
response to anoxia than old MSCs in vitro, and were more
resistant to apoptotic stimuli [26]. This was supported by a
study in a myocardial infarction (MI) model. Infarct size of
rats with experimental MI was attenuated after intramyo-
cardial injections of young MSCs, whereas injection of old
MSCs did not lead to any changes. In addition, cardiac
function was preserved after MI in all rats that received
MSCs—young, old or a mixture—but the beneﬁcial effect
on cardiac function was the largest in rats that received
only young MSCs [26]. Age does not only determine
functionality of progenitor cells but is also possibly asso-
ciated with the number of progenitor cells [27–29].
Telomere biology
Telomeres are specialized DNA structures made up of
tandem repeats (TTAGGG in humans) located at the end of
chromosomes [4, 5]. Telomeres have a critical function as
they serve as protective caps, preventing the chromosomal
ends to be accidently recognized as DNA double strands by
the DNA damage–repair system, and activation of the p53
or p16
INK4a pathway, which eventually leads to senescence
or apoptosis. The G-rich strand of the telomere, in con-
junction with specialized proteins, form a so-called telo-
mere loop (T-loop) concealing the terminal ends of the
DNA strands (Fig. 1). These specialized proteins include
telomeric repeat binding factor 1 (TRF1) and 2 (TRF2),
which can both bind directly to double-stranded telomere
DNA. Other telomere-associated proteins include the pro-
tein protection of telomeres 1 (POT1), binding directly to
single-stranded telomere DNA, and repressor activator
protein 1 (Rap1), TPP1 and TRF1-interacting nuclear
factor 2 (TIN2) (Fig. 2). Telomeres lose 30–150 base pairs
during each cell division (also known as the end replication
problem) due to the inability of DNA polymerase to fully
replicate the 3’ end of the DNA strand. Additional erosion
occurs in presence of damaging environmental factors, e.g.,
oxidative stress [30]. Because telomere length marks the
cumulative replicative history and cumulative exposure to
environmental factors, it is strongly associated to date of
birth (chronological) age and is even considered a marker
of biological/cellular aging. When the telomere reaches a
critical short length, the cell will no longer divide and can
become dysfunctional or senescent. On average, cells are
estimated to reach senescence after *50 population
Fig. 1 Simpliﬁed scheme
depicting the structure of the
telomere and its location on the
chromosome and in the cell.
Reproduced with permission
[68]
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ruption of the associated telomere-binding proteins
responsible for the three-dimensional loop structure can
induce chromosomal instability, senescence or apoptosis.
Thefunctionoftheribonucleoproteinenzymetelomerase
is the elongation of the telomere sequence by addition of
nucleotides to their ends. In most mature cells, telomerase
activity is nearly undetectable, with exceptions including
embryogenic stem cells, germline cells, malignantly trans-
formed cells and some epithelial and lymphoid progenitor
cells. Telomerase consists of two main components, telo-
merase RNA component (TERC) and telomerase reverse
transcriptase (TERT). A third component (dyskerin) serves
to stabilize the complex (Fig. 3). A less well-understood
mechanism through which telomeres can be elongated has
been named ‘alternative lengthening of telomeres’ (ALT).
This mechanism is thought to be dependent on the cellular
homologous recombination machinery, one of the systems
for the reparation of DNA double-strand breaks. The ALT
pathway is not an alternative to telomerase in cells that lack
telomerase activity. Instead, the ALT pathway acts con-
currently to telomerase [31].
Recently, the paradigm that telomeres are transcriptional
silent has been broken. Telomeric repeat-containing RNA
(TERRA) is an in length heterogeneous non-coding RNA
forming an integral component of the telomeric structure
[32, 33]. As the sequence of TERRA is complementary to
TERC, it might be involved in the regulation of telomerase
activity or regulation of the DNA damage response at short
telomeres. However, the exact function of TERRA remains
to be discovered.
Telomere length is highly variable among individuals
of the same age. Already at birth, remarkable differences
in telomere length can be detected. Several studies have
suggested that telomere length can be predicted by the
telomere length of the parents. Heritability of telomere
length has been estimated to be as high as 82% [34]. The
effect of paternal telomere length is more obvious than
that of maternal telomere length. The strength of the
association with paternal telomere length is in addition
larger for father–son than for father–daughter relation-
ships [35]. Genome-wide scans have mapped loci asso-
ciated with telomere length on chromosome 12[36],
14[37], 18[38] and 3 near TERC (component of the
enzyme telomerase) [39].
Several environmental factors are also associated with
telomere length and possible telomere attrition rate. Most
important are oxidative stress [30] and factors related to
oxidative stress such as smoking [40] and UV radiation
[41].
Fig. 2 Simpliﬁed scheme
depiction the terminal end of the
telomere concealing the
terminal single-stranded part
with help of the shelterin
complex. Reproduced with
permission [68]
Fig. 3 Schematic overview of telomerase. Active telomerase is composed from 2 RNA-complexes (TERC; only 1 depicted) and 2 telomere-
reverse-transcriptase (TERC; 1 depicted) stabilized by dyskerin. Reproduced with permission [68]
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Telomere length has been related to factors predisposing to
CHF, including hypertension [42], diabetes mellitus [43],
premature myocardial infarction [44] and activation of the
renin-angiotensin-aldosterone system (RAAS) [45]. The
effect of RAAS inhibition, however, is not clear, since
presumably all patients that suffer from CHF are taking
RAAS-inhibiting medication, leaving little or no CHF
patients without RAAS-inhibiting mediation to serve as
valid controls. Of course, the effect of RAAS inhibition
could very well be investigated in an experimental heart
failure model, but to date no data on this matter have been
reported.
Not surprisingly, patients with CHF also have shorter
telomeres compared to healthy age- and gender-balanced
controls [46]. Telomere length has even been associated
with the severity of CHF symptoms and outcome [46,
47]. In addition, worse renal function (a powerful pre-
dictor of outcome in CHF and not directly related to
vascular function [48–50]) has been associated with
telomere length in subjects with CHF [51, 52]. It is
tempting to speculate this is also due to higher senes-
cence in the kidney and consequently nephron dropout.
In apparent healthy elderly, one standard deviation of
shorter leukocyte telomere length was associated with 5%
reduced left ventricular ejection fraction and telomere
length alone accounted for 12% of the observed vari-
ability [53]. Telomere length is usually measured in
leukocytes but has also been evaluated in cardiac tissue
from patients with CHF. Patients with dilated heart
failure have *25% shorter cardiac telomeres compared
to healthy controls [54]. In aged diseased hearts charac-
terized by mild hypertrophy and biventricular failure,
shorter average telomere length was found [55]. Inter-
estingly, cardiomyocytes with severely shortened telo-
meres (\2.5 kbp) were positive for p16
INK4a, a marker
for cellular senescence. The fraction of p16
INK4a-positive
cardiomyocytes was much larger in aged diseased heart
compared to non-diseased controls. These ﬁndings are
consistent with the idea that short telomere length is
associated with increased levels of cellular senescence
facilitating—if not causing—heart failure [55].
The most prominent question concerning the associa-
tion between telomere length and heart failure is the
causality of this association. Does short telomere length
directly contribute to the development and progression of
heart failure, or does short telomere length itself or the
underlying cause of heart failure lead to accelerated
telomere shortening? An attractive explanation could be
that telomere dysfunction is a common pathway through
which risk factors act and increase cardiomyocyte
senescence and dysfunction. The diminished regenerative
capacity might also include exhaustion of the progenitor
pool with repair capacity [56–58]. Evidence for a causal
role has been provided by telomerase knockout mice.
Fifth-generation telomerase knockout mice have severely
reduced telomere length and suffer from severe left
ventricular failure, characterized by increased end-dia-
stolic left ventricular pressure, decreased maximally
developed left ventricular pressure and disturbed relaxa-
tion and contractility very similar to that observed in
human dilated cardiomyopathies [59]. On the other hand,
stabilizing telomeres by over-expression of TRF2 pre-
vents doxorubicin-induced cardiac apoptosis in wild-type
mice, but not in telomerase-deﬁcient mice [60]. However,
convincing evidence in humans for a causal role is
lacking. Shorter telomeres could be a consequence or an
epiphenomenon rather than a cause of CHF. Oxidative
stress or increased inﬂammatory status, both related to
outcome [61], could provide a true basis of the devel-
opment of CHF and at the same time explain reduced
telomere length.
Conclusions and future perspectives
Recent clinical CHF trials, for example with statins [62],
have not fulﬁlled their promises in improving prognosis of
CHF [63, 64]. Therapeutic strategies to improve myocar-
dial function and outcome in CHF are urgently needed, and
new medicines are rapidly being introduced [65–67].
Telomere biology might be involved in the biology of
aging and age-associated pathology. Telomeres are con-
nected to the basic biology of aging and trigger cellular
senescence. It still needs to be established whether telo-
mere biology is causally involved in the development of
CHF in humans. Large, prospective, longitudinal studies
are needed to provide us with more in-depth insights into
the nature of the association between telomere length and
CHF. These studies can clarify whether short telomere
length predicts the development of CHF—which possibly
supports a causal role—or telomere length merely shortens
after manifestation of CHF. Of course, strongest evidence
for a causal role would be delivered by interventional
studies that demonstrate the cardiac effects of actively
altered telomere length. At this time, however, this
approach encounters not only several practical obstacles,
but also moral objections, since our awareness of all the
consequences of telomere length manipulation is surely
incomplete. Nevertheless, answering the question on cau-
sality unambiguously in the near future is essential, as it
will allow the development of novel strategies in the
treatment and prevention of CHF, for example by beneﬁ-
cially modifying stem cells currently used in experimental
trials.
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